Pacira BioSciences, Inc. provided revenue guidance for the full year 2021. For the period, the company expected total revenue to be in the range of $540.7 to $541.7 million for 2021, compared with $429.6 million for 2020, representing an increase of at least 25.8%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.99 USD | -1.78% | +3.20% | -37.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.79% | 98Cr | |
+55.35% | 82TCr | |
+31.64% | 60TCr | |
-0.10% | 38TCr | |
+15.47% | 32TCr | |
+13.10% | 31TCr | |
+15.51% | 25TCr | |
+16.72% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira Biosciences, Inc. Provides Revenue Guidance for the Full Year 2021